VRDN
Viridian Therapeutics Inc
NASDAQ: VRDN · HEALTHCARE · BIOTECHNOLOGY
$13.30
-2.28% today
Updated 2026-04-29
Market cap
$1.37B
P/E ratio
—
P/S ratio
19.35x
EPS (TTM)
$-3.32
Dividend yield
—
52W range
$12 – $34
Volume
2.3M
Viridian Therapeutics Inc (VRDN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.41M | $4.32M | $4.32M | $2.54M | $3.34M | $4.00M | $8.39M | $4.46M | $1.05M | $2.96M | $1.77M | $314000.00 | $302000.00 | $70.85M |
| Revenue growth (YoY) | — | -2.0% | +0.1% | -41.3% | +31.5% | +20.0% | +109.5% | -46.8% | -76.5% | +182.2% | -40.2% | -82.3% | -3.8% | +23359.9% |
| Cost of revenue | $3.04M | $2.50M | $3.24M | $2.47M | $2.55M | $19.62M | $30.42M | $32.79M | $28.30M | $620000.00 | $755000.00 | $1.32M | $1.24M | $1.16M |
| Gross profit | $1.36M | $1.82M | $1.08M | $66000.00 | $789000.00 | $-15.62M | $-22.04M | $4.46M | $-27.25M | $2.96M | $1.77M | $314000.00 | $302000.00 | $69.69M |
| Gross margin | 31.0% | 42.1% | 24.9% | 2.6% | 23.6% | -390.2% | -262.8% | 100.0% | -2595.6% | 100.0% | 100.0% | 100.0% | 100.0% | 98.4% |
| R&D | $225378.00 | $96847.00 | $293000.00 | $1.00M | $888000.00 | $19.62M | $30.42M | $34.79M | $28.30M | $56.89M | $100.89M | $159.76M | $238.25M | $338.93M |
| SG&A | $2.91M | $1.79M | $7.03M | $7.69M | $7.91M | $10.91M | $11.05M | $11.65M | $13.27M | $25.80M | $35.18M | $95.00M | $61.08M | $95.31M |
| Operating income | $-4.03M | $-196213.00 | $-6.87M | $-11.19M | $-12.51M | $-26.53M | $-33.08M | $-41.98M | $-110.38M | $-79.73M | $-134.30M | $-254.45M | $-299.04M | $-363.39M |
| Operating margin | -91.4% | -4.5% | -159.0% | -440.8% | -374.8% | -662.8% | -394.5% | -941.0% | -10512.4% | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| EBITDA | $-3.88M | $-47898.00 | $-6.72M | $-11.00M | $-12.51M | $-25.82M | $-31.55M | $-40.75M | $-40.28M | $-79.29M | $-129.13M | $-235.37M | $-265.66M | $-336.49M |
| EBITDA margin | -88.1% | -1.1% | -155.6% | -433.5% | -374.8% | -645.0% | -376.2% | -913.5% | -3836.2% | -2676.0% | -7287.4% | -74957.0% | -87967.9% | -474.9% |
| EBIT | $-4.03M | $-196213.00 | $-6.87M | $-11.19M | $-12.85M | $-26.13M | $-31.83M | $-41.04M | $-40.52M | $-79.41M | $-129.39M | $-235.89M | $-266.90M | $-337.65M |
| Interest expense | $1.59M | $1.96M | $1.02M | $141000.00 | $95000.00 | $383000.00 | $873000.00 | $835000.00 | $508000.00 | $3000.00 | $486000.00 | $1.85M | $3.05M | $4.95M |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-7.21M | $-2.16M | $-7.89M | $-11.33M | $-12.67M | $-26.51M | $-32.70M | $-41.87M | $-110.72M | $-79.41M | $-129.87M | $-237.73M | $-269.95M | $-342.60M |
| Net income growth (YoY) | — | +70.1% | -265.3% | -43.6% | -11.9% | -109.2% | -23.4% | -28.0% | -164.4% | +28.3% | -63.5% | -83.0% | -13.6% | -26.9% |
| Profit margin | -163.7% | -50.0% | -182.6% | -446.3% | -379.8% | -662.3% | -390.0% | -938.6% | -10544.3% | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |